Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyBlue Cross Blue Shield ND IMRT Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North DakotaPolicy 164

    Intensity Modulated Radiotherapy (IMRT) of the Central Nervous System (CNS), Head, Neck, and Thyroid

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - North Dakota Policy 164 alerts

    Get alerted when Policy 164 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when IMRT for central nervous system, head, neck, and thyroid tumors may be considered medically necessary and applies to provider coverage and prior-authorization requests, subject to applicable contract terms.

    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyIMRT for CNS, Head, Neck, and Thyroid Tumors
    Policy CodePolicy 164
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateSeptember 1, 2026
    Key ActionSubmit clinical history, chart notes, relevant imaging reports, and, when applicable, expected survival documentation for prior-authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Potentially medically necessary indication categories
    <21 yearsPediatric CNS tumor age threshold
    ≥4 monthsExpected survival for hippocampal-avoiding IMRT
    5 mmMetastasis distance outside hippocampal margin
    93Related clinical and practice-guideline references

    Medical Necessity Criteria

    Medically Necessary Indications

    Intensity-modulated radiotherapy (IMRT) of the head, neck, thyroid, and central nervous system may be considered medically necessary when <strong>any one</strong> of the following criteria is met. This policy addresses specific indications only. For requests where IMRT is the only way to meet published dose/volume constraints for organs at risk, see Medicine, Policy No. 167.

    ANY of the following

    • There is documented prior radiation treatment to the planned target volume.
    • Definitive radiotherapy for a pediatric individual younger than 21 years of age with a central nervous system (CNS) tumor.

      For palliative treatment of pediatric CNS tumors and treatment of adults with CNS tumors and no prior radiation, see Medicine, Policy No. 167.

    • Hippocampal-avoiding IMRT for brain tumor metastases

      • Metastases are outside a 5-mm margin around the hippocampi.
      • Clinical documentation shows expected survival is at least 4 months.≥ 4 months
    • Treatment of head and neck cancers, including primary and recurrent cancers arising from the oral cavity and lip, larynx, hypopharynx, oropharynx, nasopharynx, paranasal sinuses and nasal cavity, salivary glands, and soft tissue sarcomas, unusual histologies, or occult primaries in the head and neck region.
    • Treatment of lymphomas in the head and neck region, excluding follicular lymphoma and MALT and marginal zone lymphomas.
    • Treatment of thyroid cancer when ANY of the following is met

      • Locoregional recurrence.
      • Anaplastic thyroid cancer.
      • Node-positive or node-recurrent disease.
      • Documented muscle invasion.

    Select Potentially Medically Necessary Indications

    IMRT may be considered medically necessary for the following select indications when the applicable policy criteria are met.

    Select indications

    • Reirradiation of CNS, head, neck, or thyroid tumors in an area previously treated with radiation.

      Research indicates potential for improved outcomes and fewer adverse events compared with other radiotherapy techniques when policy criteria are met.

    • Treatment of CNS tumors in pediatric patients.

      Research indicates potential for improved outcomes and fewer adverse events compared with other radiotherapy techniques when policy criteria are met.

    • Hippocampal-avoiding IMRT for brain tumor metastases.

      Research indicates potential for improved outcomes and fewer adverse events for some patients when policy criteria are met.

    • Treatment of head and neck cancers and lymphomas in the head and neck region, excluding follicular lymphoma and MALT and marginal zone lymphomas.

    Thyroid Cancer Near Organs at Risk

    IMRT may be considered for thyroid cancer located near organs at risk when all of the following conditions are met:

    ALL of the following

    • The thyroid cancer is in close proximity to organs at risk, including the esophagus, salivary glands, or spinal cord.
    • Three-dimensional conformal radiotherapy planning is unable to meet dose-volume constraints for normal tissue tolerance.

    The head and neck cancer category excludes skin cancer.

    The head and neck lymphoma category excludes follicular, MALT, and marginal zone lymphomas.

    Head and neck follicular lymphoma and MALT and marginal zone lymphomas are excluded from coverage under the head and neck lymphoma category.

    Other central nervous system, head, neck, and thyroid cancer indications outside the select policy criteria are excluded.

    IMRT is not medically necessary for tumors of the head, neck, thyroid, and central nervous system that do not meet Criterion I. For requests where IMRT is the only way to meet published dose/volume constraints for organs at risk, see Medicine, Policy No. 167.

    For all other indications, IMRT has not been shown to improve net health outcomes compared with other treatment modalities. Therefore, except for the select group of patients identified in the policy criteria, IMRT is not medically necessary for all other central nervous system, head, neck, and thyroid cancers.

    Covered Procedure Codes

    CPT and HCPCS IMRT planning, delivery, and related servicesmixed
    77399Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services
    77301Intensity modulated radiotherapy plan, including dose volume histograms for target and critical structure partial tolerance specification.
    77338Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
    77386Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
    G6015Intensity modulated radiation treatment delivery, includes guidance and tracking, when performed; complex

    Authorization and Documentation Requirements

    Prior Authorization

    Submit Records for Prior Authorization

    Submit the required records with the prior authorization request so the plan can determine whether the IMRT policy criteria are met. Missing information may affect the review and decision outcome.

    • Clinical history
    • Physical or chart notes
    • Relevant imaging reports
    • For hippocampal-avoiding IMRT for brain tumor metastases, documentation of expected survival
    • Quality assurance for 3D and IMRT submitted plans is not required with a preauthorization request.
    Documentation Required

    Required Clinical and Imaging Documentation

    Provide the clinical and imaging documentation needed to establish medical necessity under the applicable policy criteria. For hippocampal-avoiding IMRT for brain tumor metastases, include documentation that expected survival is at least 4 months.

    Clinical and Technical Background

    Intensity-modulated radiotherapy (IMRT) is a radiation technique that conforms treatment more closely to the target by modulating the intensity of multiple shaped radiation beams. This approach is used to optimize delivery to the treatment area while reducing radiation exposure to surrounding healthy tissues.

    Key Terms

    Intensity-modulated radiotherapy (IMRT)
    TechniqueRadiation therapy that conforms closely to the targeted tumor shape.
    Beam modulationModulates the intensity of overlapping radiation beams using multiple shaped treatment fields.
    Treatment planningUses computer-based inverse planning to optimize beam locations, shapes, and intensities.
    Organs at risk
    DefinitionNormal tissues whose radiation sensitivity may significantly influence treatment planning or the prescribed radiation dose.
    Clinical importanceThese tissues may be particularly vulnerable to clinically important complications from radiation toxicity.
    Policy Summary
    PayerBlue Cross Blue Shield - North Dakota
    PolicyIMRT for CNS, Head, Neck, and Thyroid Tumors
    Policy CodePolicy 164
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Last ReviewDec 1, 2025
    Next Review DateSeptember 1, 2026
    Key ActionSubmit clinical history, chart notes, relevant imaging reports, and, when applicable, expected survival documentation for prior-authorization review.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Procedure CodesAuthorization and Documentation RequirementsClinical and Technical BackgroundKey Terms

    Research shows comparable tumor control and improvements in complication rates when policy criteria are met.

  1. Treatment of thyroid cancer.

    Although research is limited, IMRT may reduce radiation exposure to critical nearby structures when policy criteria are met.

    • Clinical history and physical/chart notes
    • Relevant imaging reports documenting that the policy criteria are met
    • Expected survival documentation for hippocampal-avoiding IMRT for brain tumor metastases
    • The applicable hippocampal criterion requires expected survival of ≥4 months.
    Denial Risk

    Failure to Meet Qualifying Criteria

    IMRT is considered not medically necessary for tumors of the head, neck, thyroid, or central nervous system that do not meet the policy criteria. Requests that meet only published dose/volume constraints for organs at risk should use Medicine, Policy No. 167.

    • Failure to meet Criterion I results in a not-medically-necessary determination.
    • Apply the policy criteria to the submitted clinical and imaging documentation before requesting authorization.
    Billing Rule

    Contract Exclusions

    Contract terms control benefit determinations when they conflict with this medical policy. Contracts exclude services or procedures considered investigational or cosmetic, and providers may bill members for those services.

    • Inform members before rendering investigational or cosmetic services that they are likely to be financially responsible.
    • Member financial responsibility may apply to excluded investigational or cosmetic services.
    Denial Risk

    Indication Outside Covered Criteria

    Except for the select indications identified in the policy criteria, IMRT is not medically necessary for cancers of the central nervous system, head, neck, or thyroid. The policy does not establish coverage for all other indications.

    • Coverage is limited to the qualifying CNS, head and neck, lymphoma, and thyroid indications described in the policy.
    • Other CNS, head, neck, and thyroid cancers are not medically necessary under this policy.
    Denial Risk

    Excluded Lymphoma Types

    IMRT may be considered medically necessary for qualifying lymphomas in the head and neck region, but follicular lymphoma and MALT or marginal zone lymphomas are excluded from the covered lymphoma indication.

    • Excluded: follicular lymphoma
    • Excluded: MALT lymphoma
    • Excluded: marginal zone lymphoma
    Planning relevance
    Their sensitivity and potential toxicity are considered when establishing treatment plans and dose limits.
    Examples of organs at risk
    Brain and central nervous systemTemporal lobe, hippocampus, brain stem, and spinal cord.
    Auditory structuresCochlea.
    Visual and ocular structuresOptic nerve, optic chiasm, lens, retina, and lacrimal gland.
    Intensity-modulated radiotherapy (IMRT)
    DefinitionA radiation treatment technique evaluated against three-dimensional conformal radiotherapy for target conformity, dose homogeneity, organ-at-risk sparing, toxicity, and clinical outcomes.
    Target planningComparative treatment-planning studies assess how closely IMRT conforms to the target and how evenly dose is distributed within it.
    Normal-tissue planningComparisons also assess organ-at-risk sparing and whether dosimetric advantages translate into reduced toxicity or improved clinical outcomes.
    Three-dimensional conformal radiotherapy (3D-CRT)
    DefinitionAn alternative radiation delivery technique used as a comparator to IMRT in treatment-planning and clinical studies.
    Comparative use3D-CRT is evaluated against IMRT for target coverage, dose conformity, organ-at-risk dose, toxicity, and clinical outcomes.
    Evidence contextComparative studies assess whether the potential normal-tissue-sparing benefits of IMRT translate into meaningful health outcomes compared with 3D-CRT.
    Organs at risk (OAR)
    DefinitionNormal tissues adjacent to or affected by the radiation treatment field.
    ExamplesBrainstem, optic chiasm, optic nerves, lens, retina, spinal cord, and eyes.
    Treatment-planning roleOARs are considered when evaluating dose distributions and limiting radiation exposure to normal tissues.
    Hippocampal-avoiding whole-brain radiotherapy (HA-WBRT)
    DefinitionWhole-brain radiotherapy designed to reduce radiation exposure to the hippocampus.
    Delivery approachTypically delivered using intensity-modulated radiotherapy (IMRT) in the cited evidence.
    Treatment objectiveThe hippocampal-avoiding approach is intended to reduce loss of cognitive function compared with conventional whole-brain radiotherapy.